DarioHealth Corp. Focuses on Earnings Outlook and Cost‑Saving Evidence

DarioHealth Corp. (NASDAQ: DRIO), a digital health company headquartered in New York, announced a series of developments on 12 November 2025 that underscore its emphasis on earnings performance and real‑world evidence of cost savings for employer‑sponsored health plans.

Earnings Forecast for the September 2025 Quarter

On 13 November 2025, DarioHealth will present its financial results for the quarter ended 30 September 2025. Analyst consensus indicates a diluted earnings‑per‑share (EPS) of ‑4.90 USD, an improvement of 2 % relative to the previous year’s EPS of ‑5.00 USD. Revenue expectations are lower, with analysts forecasting $5.7 million compared with $7.4 million in the corresponding period last year, representing a 23.58 % decline.

For the full fiscal year, analysts project a diluted loss per share of ‑15.995 USD versus ‑12.200 USD in the prior year. Revenue for the year is expected to be $23.9 million, down from $27.0 million reported last year.

The company’s current share price as of 11 November 2025 was $11.75; its 52‑week range has spanned $5.935 to $31.00.

Real‑World Evidence of Medical Cost Reduction

DarioHealth presented new data at ISPOR Europe 2025, a leading health‑economics conference, demonstrating that employer members using the platform experienced significant reductions in medical costs. The retrospective observational analysis, titled “Preliminary Observational Analysis of Digital Health Platform Associated with Medical Cost Changes in Employer Population,” is the company’s first publication based on claims data to quantify economic impact.

The study highlighted that high‑risk members who engaged with Dario’s multi‑condition digital therapeutics platform incurred lower overall medical expenses compared with peers who did not use the platform. The findings support the company’s claim that its data‑driven, user‑centric interventions can deliver tangible cost savings for employers.

Market Context for Digital Therapeutics

The broader digital therapeutics market remains a key growth driver for DarioHealth. According to a recent report from TBRC Business Research, the global market for digital therapeutics targeting fibromyalgia is projected to reach $2.53 billion by 2029, growing at a compound annual growth rate of 20.9 %. The report notes that the fibromyalgia segment alone is expected to grow from $0.98 billion in 2024 to $1.19 billion in 2025, reflecting a 21.3 % CAGR.

These market dynamics reinforce the strategic relevance of DarioHealth’s platform, which offers personalized, data‑driven interventions across a range of chronic conditions, including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Key Takeaways

  • DarioHealth’s upcoming quarterly and annual results are expected to show improved EPS but declining revenue.
  • New claims‑based evidence demonstrates cost savings for employer‑sponsored populations using the platform.
  • The digital therapeutics market, particularly for fibromyalgia, is expanding rapidly, providing a favorable environment for DarioHealth’s growth.